

1   **Title:**

2   Sting orchestrates the crosstalk between polyunsaturated fatty acids metabolism and  
3   inflammatory responses

4

5   **Authors:**

6   Isabelle K. Vila<sup>1\*</sup>, Hanane Chamma<sup>1</sup>, Alizée Steer<sup>1</sup>, Clara Taffoni<sup>1</sup>, Line S. Reinert<sup>2</sup>, Evgenia  
7   Turtoi<sup>3,4</sup>, Mathilde Saccas<sup>1</sup>, Johanna Marines<sup>1,5</sup>, Lei Jin<sup>6</sup>, Xavier Bonnefont<sup>7</sup>, Soren R.  
8   Paludan<sup>2</sup>, Dimitrios Vlachakis<sup>8,9,10</sup>, Andrei Turtoi<sup>3,4</sup>, Nadine Laguette<sup>1\*</sup>

9

10   **Affiliations:**

11   <sup>1</sup> Institut de Génétique Humaine, CNRS, Université de Montpellier, Molecular Basis of  
12   Inflammation Laboratory, Montpellier, France

13   <sup>2</sup> Department of Biomedicine, University of Aarhus, Aarhus, Denmark

14   <sup>3</sup> Tumor Microenvironment Laboratory, Institut de Recherche en Cancérologie de Montpellier,  
15   Université de Montpellier, INSERM U1194, 34000 Montpellier, France

16   <sup>4</sup> Platform for Translational Oncometabolomics, Biocampus, CNRS, INSERM, Université de  
17   Montpellier, Montpellier, France.

18   <sup>5</sup> Azelead, 377 rue du Pr. Blayac, 34080 Montpellier

19   <sup>6</sup> Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208

20   <sup>7</sup> Institut de Génomique Fonctionnelle (IGF), University Montpellier, CNRS, INSERM, 34094  
21   Montpellier, France

22   <sup>8</sup> Laboratory of Genetics, Department of Biotechnology, School of Applied Biology and  
23   Biotechnology, Agricultural University of Athens, 75 Iera Odos, 11855 Athens, Greece

24   <sup>9</sup> Division of Endocrinology and Metabolism, Center of Clinical, Experimental Surgery and  
25   Translational Research, Biomedical Research Foundation of the Academy of Athens, 11527  
26   Athens, Greece

27   <sup>10</sup> University Research Institute of Maternal and Child Health & Precision Medicine, Medical  
28   School, National and Kapodistrian University of Athens, 11527 Athens, Greece

29   \* To whom correspondence should be addressed

30

31

32

33   **Corresponding authors:** Nadine Laguette (nadine.laguette@igh.cnrs.fr) and Isabelle K. Vila  
34   (Isabelle.vila@igh.cnrs.fr)

35 **Summary:**

36 Inflammatory disorders are major health issues in which immune function and metabolic  
37 homeostasis are concertedly altered. Yet, the molecular mechanisms coordinating innate and  
38 metabolic pathways in homeostatic conditions are poorly understood. Here, we unveil a  
39 negative regulatory feedback loop involving the Stimulator of interferon genes (Sting) and the  
40 Fatty acid desaturase 2 (Fads2). At steady state, Sting regulates FA metabolism by repressing  
41 the activity of the Fads2 enzyme responsible for the desaturation of polyunsaturated FAs  
42 (PUFAs). Importantly, Sting activation increased Fads2 activity, while antagonizing Fads2  
43 enhanced Sting activation, promoting the establishment of an anti-viral state. Remarkably, the  
44 cross-regulation between Sting and Fads2 is mediated by the cyclic GMP-AMP (cGAMP) Sting  
45 agonist and PUFAs. Indeed, we found that PUFAs inhibit Sting activation, while Sting agonists  
46 bind Fads2. Thus, our study identifies Sting as a master regulator of FA metabolism, and PUFAs  
47 as modulators of Sting-dependent inflammation. The interplay between Fads2 and Sting  
48 determines the fine-tuning of inflammatory responses, but comes at the expense of metabolic  
49 alterations, which are critical to consider in human pathologies associated with aberrant Sting  
50 activation.

51

52 **Introduction:**

53 The endoplasmic-reticulum (ER)-resident Stimulator of interferon genes (Sting) adaptor  
54 protein is central to the mounting of inflammatory responses in the presence of pathological  
55 nucleic acids, including dsDNA (Ishikawa et al., 2009). Indeed, aberrant dsDNA accumulation  
56 under stress conditions (Bai et al., 2017; King et al., 2017) or following pathogen infections  
57 (Gao et al., 2013a) can be detected by the cyclic GMP-AMP (cGAMP) synthase (cGAS) (Sun  
58 et al., 2013), that catalyzes the production of cGAMP (Ablasser et al., 2013; Gao et al., 2013b).  
59 This second messenger interacts with Sting (Zhang et al., 2013), promoting its activation  
60 through the recruitment of the Tank binding kinase 1 (Tbk1), resulting in phosphorylation-  
61 dependent activation of transcription factors, such as the Interferon regulatory factor 3 (Irf3)  
62 (Liu et al., 2015). This signaling pathway triggers the production of inflammatory cytokines  
63 and type I Interferons (IFNs) (Ishikawa et al., 2009). Dysregulations of Sting-associated  
64 signaling have been reported in a vast array of human pathologies. Yet, Sting function in  
65 absence of inflammatory challenge is unknown.

66

67 **Results:**

68 **Absence of STING Leads to Metabolic Improvements *In Vivo***

Because homeostasis requires tight regulation of metabolic and immune pathways (Brestoff and Artis, 2015; Buck et al., 2017), we questioned the impact of Sting ablation on metabolic parameters, at steady-state. Under normal diet, wild-type (WT) and *Sting*<sup>-/-</sup> mice do not exhibit spontaneous inflammation (Figure 1A), nor differences in body weight (Figure 1B) and composition (Figure 1C). Yet, *Sting*<sup>-/-</sup> mice present increased food intake (Figure 1D) and improved insulin-independent (Figure 1E and S1A) glucose management (Figure 1F), coupled to decreased hepatic gluconeogenesis (Figure 1G). Indirect calorimetry measurements showed that *Sting*<sup>-/-</sup> mice consume more oxygen (Figure 1H) and present higher energy expenditure during the light phase (Figure 1I), in absence of change in circadian rhythm (Figure S1B) or spontaneous locomotor activity (Figure 1J). In addition, *Sting*<sup>-/-</sup> mice, display increased thermogenesis (Figure 1K). Intriguingly, no significant change was measured in the expression of thermogenic program genes in the brown adipose tissue (Figure S1C), while *Uncoupling Protein 1 (Ucp1)* and *Peroxisome proliferator-activated receptor-gamma coactivator-1alpha (Pgc-1α)* mRNA levels were increased in the visceral white adipose tissue (Figure 1L), reflecting the activation of browning pathways (Seale et al., 2007). Furthermore, the survival of *Sting*<sup>-/-</sup> mice is increased as compared to WT mice under high fat diet (Figure 1M). Finally, metabolic phenotyping of cGAS-deficient mice and of conditional myeloid cell-specific *Sting*<sup>-/-</sup> mice (Figure S1D-I) confirmed that metabolic alterations witnessed in *Sting*-deficient mice is independent of its canonical innate immune function. Therefore, absence of *Sting* is sufficient to cause global metabolic improvements *in vivo*.

## Sting interacts with and inhibits the Fatty Acid Desaturase 2

To identify the molecular mechanism through which *Sting* regulates metabolic homeostasis, we performed tandem-affinity purification of Flag- and HA-tagged *Sting* (F/HA-*Sting*) stably expressed in mouse embryonic fibroblasts (MEF) knockout of *Sting* (MEF<sup>*Sting*<sup>-/-</sup></sup>). Immunopurified material was either silver-stained (Figure 2A) or analyzed by Mass spectrometry to identify *Sting* protein partners. Besides known *Sting* interactors, this approach revealed a large number of proteins involved in metabolic pathways (Table S1), notably including the RE-resident Fatty acid desaturase 2 (Fads2). Fads2 is the first, rate-limiting enzyme in the desaturation of linoleic acid [LA (18:2n-6, or Omega-6)] and α-linolenic acid [ALA (18:3n-3, Omega-3)] precursors (Nakamura and Nara, 2004), to generate polyunsaturated fatty acids (PUFAs) (Figure 2B). Precisely, Fads2 catalyses the desaturation of ALA into eicosapentaenoic acid (EPA), and subsequently into docosahexaenoic acid (DHA). Desaturation of LA into Dihomo-γ-linolenic acid (DGLA) also requires Fads2 (Nakamura and Nara, 2004), while further desaturation into arachidonic acid (AA) is catalysed by the Fatty acid

103 desaturate 1 (Fads1) (Leonard et al., 2000). Dedicated enzymes further process these PUFAs  
104 into Oxylipins that influence numerous physiological processes (Gabbs et al., 2015). The  
105 interaction between Fads2 and Sting was verified by Western blot (WB) analysis of Flag-  
106 immunoprecipitated F/HA-Sting (Figure 2C). Conversely, Flag-immunoprecipitation of Flag-  
107 tagged Fads2 (F-Fads2) allowed co-immunoprecipitation of Sting, but not of Tbk1 (Figure 2D).  
108 Thus, we show that Fads2 is a protein partner of Sting, independently of Tbk1 and of pro-  
109 inflammatory stimulation.

110 Because PUFAs are ligands of transcription factors that control thermogenesis (Fan et  
111 al., 2019), changes in PUFAs levels could be expected to promote the metabolic alterations  
112 observed in the absence of Sting (Figure 1). We used liquid chromatography coupled to mass  
113 spectrometry (LC-MS) to quantify PUFAs and their derivatives in liver and adipose tissue (AT)  
114 samples from WT and *Sting*<sup>-/-</sup> mice. Partial least squares discriminant analysis (PLS-DA) of  
115 LC-MS data showed that WT and *Sting*<sup>-/-</sup> liver and AT samples are significantly different  
116 (Figure S2A-B). Correlation analysis showed a shift in PUFA content, leading to accumulation  
117 of Omega-3 derivatives (Figure S2C-D). Although no significant shift in the total Omega-  
118 6/Omega-3 ratio was measured (Figure 2E), the total amount of derivatives from the main  
119 PUFAs families in mice liver samples showed that absence of Sting leads to significantly  
120 increased levels of DGLA and DHA derivatives (Figure 2F), coupled to increased Fads2  
121 activity in *Sting*<sup>-/-</sup> mice (Figure 2G). Similar increase in PUFAs deriving from Fads2 activity  
122 was measured in MEF<sup>*Sting*<sup>-/-</sup></sup> as compared to WT-MEFs, but not in MEF<sup>cGAS<sup>-/-</sup></sup> (Figure S2E-F).  
123 Importantly, mRNA levels of the *Pgc-1α* and *PR domain containing 16 (Prdm16)* transcription  
124 factors involved in browning (Seale et al., 2007), were upregulation in *Sting*<sup>-/-</sup>, but not in cGAS<sup>-</sup>  
125 MEFs (Figure 2H). This strongly supports that changes in PUFAs pools drive activation of  
126 thermogenesis program in absence of Sting.

## 127 **Sting Activation Promotes Fads2 activity**

128 Because Sting activation leads to its degradation (Konno et al., 2013), we hypothesized  
129 that following Sting activation, the block of Fads2 activity would be alleviated. We used  
130 dsDNA transfection to activate Sting-dependent signalling (Figure 3A) and Sting degradation  
131 (Figure 3B), prior to analysis of PUFAs. We observed an increase in PUFAs deriving from  
132 Fads2 activity, including DHA (Figure 3C), accompanied by increased expression of *Pgc-1α*  
133 and *Prdm16* (Figure S3A), without significant shift in the Omega-6/Omega-3 balance (Figure  
134 3D). Intriguingly, we also observed decreased Fads2 levels following Sting activation (Figure  
135 3A), independently of type I IFN production (Figure S3B-C). This is in agreement with previous  
136 reports that Fads2 levels are decreased following its over-activation (Ralston et al., 2015). Of

137 note, decreased Fads2 levels were also observed following infection with the Herpes Simplex  
138 Virus type I (HSV-1) DNA virus known to promote Sting activation (Figure S3D-F). Thus,  
139 acute activation-dependent decrease of Sting levels promotes Fads2 activity and metabolic  
140 reprogramming.

141 To assess the impact of chronic Sting activation on Fads2 activity, we used MEF  
142 knockout of the Three prime exonuclease 1 (MEF<sup>Trex1<sup>-/-</sup></sup>) that present with spontaneous chronic  
143 Sting activation (Ablasser et al., 2014) (Figure 3E). Absence of Trex1 correlates with decreased  
144 Fads2 protein levels, in absence of change in Sting protein levels (Figure 3F). Analysis of  
145 PUFAs and derivatives in WT and Trex1<sup>-/-</sup> MEFs showed increased DGLA and DHA levels,  
146 indicating increased Fads2 activity (Figure 3G). However, we also measured increased levels  
147 of AA in absence of Trex1 (Figure 3G), together with an increased Omega-6/Omega-3 ratio  
148 (Figure 3H). While this supports our model whereby Sting activation promotes increased Fads2  
149 activity, this also indicates that Sting degradation is not the sole parameter modulating Fads2  
150 activity upon chronic Sting activation.

### 151 **cGAMP and PUFAs Orchestrate the Crosstalk Between Fads2 and Sting**

152 Because Sting activation requires its interaction with dinucleotides, we hypothesized  
153 that the latter may participate to the control of Fads2 activation. We first tested this hypothesis  
154 *in silico* by docking cGAMP and the 5,6-dimethylxanthenone-4-acetic acid (DMXAA) Sting  
155 agonist into Fads2. To this aim, we used the resolved crystal of Sting in complex with cGAMP  
156 (PDB ID: 6WD4) and the molecular model of Fads2 as starting biological systems. This  
157 predicted that cGAMP and DMXAA can dock into Fads2, adopting similar conformation  
158 (Figure 4A, left and right panels), achieving analogous interactions and docking energies  
159 (Figure S4A and Table S2). We confirmed the interaction between cGAMP and Fads2 using *in*  
160 *vitro* binding assays (Figure 4B). In addition, we treated cGas<sup>-/-</sup>, Sting<sup>-/-</sup>, and WT-MEF with  
161 DMXAA, or performed dsDNA transfection to induce cGAMP production, prior to analysis of  
162 Fads2 protein levels. This showed that Fads2 levels are decreased in presence of DMXAA,  
163 regardless of the expression of cGas and Sting (Figure 4C), while dsDNA transfection-induced  
164 Fads2 degradation was reduced in the absence of cGas (Figure S4B). Thus, altogether these  
165 data show that Fads2 is a target of dinucleotides targeting Sting.

166 Intriguingly, molecular docking analysis between PUFAs and Sting, predict that PUFAs  
167 can dock to the cGAMP-binding domain of Sting (Figure 4A, right panels). Indeed, cGAMP,  
168 DMXAA and PUFAs, adopt similar conformations in *in silico* docking experiments performed  
169 with Sting or Fads2 (Figure S4A), achieving analogous binding energies (Table S2).  
170 Furthermore, Sting and Fads2 showed strong structural similarity, both with regards to the 3D

171 arrangement of the docking site anatomy, and in terms of hydrophobicity, electrostatics and  
172 solvent accessibility (Figure S4A). This suggested that PUFAs are potential ligands of Sting.  
173 We thus tested the impact of administrating ALA and LA precursors to cells prior to assessment  
174 of DMXAA-induced Sting activation. Both treatments decreased DMXAA-dependent  
175 expression of *Ifnβ* and of the *Cxcl10* interferon stimulated gene (ISG) (Figure 4D). Consistently,  
176 knock-down of Fads2, which caused a global decrease of Fads2 by-products (Figure S4C), led  
177 to increased *Ifnβ* and *Cxcl10* expression (Figure 4E-F), together with decreased expression of  
178 thermogenesis program genes (Figure S4D). Finally, antagonizing Fads2, using shRNAs or an  
179 inhibitor, led to decreased infection by HSV-1 (Figure 4G), consistent with the establishment  
180 of an antiviral state. Thus, we establish that PUFAs as inhibitors of Sting. Altogether, we show  
181 that Fads2 and Sting cooperate for the maintenance of global homeostasis, through fine-tuning  
182 of inflammatory and metabolic pathways (Figure 4H).

183

#### 184 **Discussion:**

185 Altogether, we uncover a central role of Sting in the regulation of metabolic  
186 homeostasis, independently of its reported innate immune function. Indeed, we show that Sting  
187 inhibits Fads2 activity, thereby altering PUFAs pools. Absence of Sting thus increases the levels  
188 of Omega-3-derived PUFAs that in turn improve glucose handling (Sirtori and Galli, 2002),  
189 prevent obesity-associated glucose intolerance (Belchior et al., 2015; Derosa et al., 2016) and  
190 increase cardiovascular protection (Gonzalez-Periz et al., 2009). In agreement, we found that  
191 absence of Sting leads to better survival of mice under high fat diet. Furthermore, Omega-3-  
192 derived PUFAs can promote white adipose tissue browning (Fernández-Galilea et al., 2020), a  
193 process in which increased *Ucp1*, *Pgc-1α* and *Prdm16* expression is crucial (Ghandour et al.,  
194 2018). We found that absence of Sting promotes Fads2-dependent induction of these  
195 thermogenic factors, demonstrating that metabolic remodelling in absence of Sting requires  
196 Fads2. In addition, we show that Sting agonists, can directly interact with Fads2 and promote  
197 its degradation, establishing Fads2 as a direct target of cGAMP and DMXAA. This implies that  
198 in pathologies presenting with chronic Sting activation, Sting-dependent modulation of Fads2  
199 activity may feed metabolic comorbidities such as dyslipidemia (Lira et al., 2014) or cachexia  
200 (Baazim et al., 2019). Furthermore, small molecules targeting Sting (Haag et al., 2018; Wu et  
201 al., 2020) can be expected to alter Fads2 activity and downstream production of inflammatory  
202 lipid mediators.

203 That PUFAs can inhibit Sting, reveals a previously unappreciated link between fatty  
204 acid metabolism and innate immune responses. Indeed, there are indications that diet

205 intervention and modulation of Omega-3 or Omega-6 intake can impact immune and antiviral  
206 responses (DiNicolantonio and O'Keefe, 2018), although the involved molecular mechanism  
207 remaining poorly understood. We reveal that Fads2 activity and PUFAs can inhibit Sting  
208 activation. While this process may serve in the resolution of Sting-dependent inflammation,  
209 dietary habits that impact the substrates provided to Fads2 for desaturation (Galland, 2010; Tosi  
210 et al., 2014) may directly influence Sting activation and alter immune function (Sen et al.,  
211 2019). In addition, we show that modulating Fads2 activity impacts on the establishment of an  
212 antiviral state. This is in agreement with previous reports that PUFAs levels can both influence  
213 (Berra et al., 2017) and be influenced by HSV-1 infection (Zhang et al., 2020). Thus, we reveal  
214 a novel mechanism through which PUFAs contribute to the fine-tuning of inflammatory  
215 responses and identify Sting as a trigger of thermogenic program. Altogether, our findings offer  
216 unprecedented insight into the crosstalk between innate immune processes and metabolic  
217 regulation. Targeting this crosstalk in pathologies presenting with chronic inflammation, bears  
218 the promise to alleviate associated comorbidities.

219

220 **Acknowledgements:** We thank M Benkirane, G Cavalli, J Déjardin and B de Massy for  
221 discussions and comments. We acknowledge: the SIRIC Montpellier Cancer Grant  
222 (INCa\_Inserm\_DGOS\_12553), Metamus-RAM and iExplore-RAM animal facilities, the  
223 “Laboratoire de Mesures Physiques” of the University of Montpellier, for access to the Mass  
224 Spectrometry instruments, the MRI imaging facility, member of the national infrastructure  
225 France-BioImaging infrastructure supported by the French National Research Agency (ANR-  
226 10-INBS-04, “Investments for the future”) and Ross Tomaino from the “Taplin Mass  
227 Spectrometry Facility” of the Harvard Medical School, for Mass Spectrometry analysis. Work  
228 in NL’s laboratory is supported by the European Research Council (ERC-Stg CrIC: 637763,  
229 ERC-PoC DIM-CrIC: 893772), “LA LIGUE pour la recherche contre le cancer” and the  
230 “Agence Nationale de Recherche sur le SIDA et les Hépatites virales” (ANRS). HC is supported  
231 by a PhD fellowship from “LA LIGUE pour la recherche contre le cancer”. CT was supported  
232 by Merck Sharp and Dohme Avenir (MSD-Avenir – GnoSTic) program, followed by an ANRS  
233 fellowship. JM is supported by a “Conventions Industrielles de Formation par la Recherche”  
234 (CIFRE) fellowship from the “Agence Nationale de Recherche Technologie” (ANRT). AS is  
235 supported by the ERC-PoC DIM-CrIC (893772). IKV was supported by the ERC-Stg CrIC  
236 (637763) followed by the Fondation pour la Recherche Médicale (ARF20170938586). Work in  
237 SRP’s laboratory is supported by the European Research Council (ERC-AdG ENVISION;  
238 786602), The Novo Nordisk Foundation (NNF18OC0030274), and the Lundbeck Foundation

239 (R198-2015-171; R268-2016-3927). Work in AT's laboratory is supported by a SIRIC  
240 Montpellier Cancer Grant INCa\_Inserm\_DGOS\_12553, the Foundation de France (grant no.  
241 00078461) and a LabEx MabImprove Starting Grant. XB is supported by ANR GH-gen (ANR-  
242 18-CE14-0017).

243 **Author contributions.** IKV and NL conceived the study and designed experiments. IKV, HC,  
244 AS, CT, LSR, ET, MS, JM, XB, DV, AT performed experiments. IKV, SRP, DV, AT and NL  
245 supervised the study. JL provided mice and mice tissues samples. IKV, DV, AT and NL  
246 analyzed data and prepared figures. IKV, DV, AT and NL wrote the manuscript. All authors  
247 read and approved the final version of the manuscript.


248 **Competing interests.** The authors declare no competing interest.

249 **Materials & Correspondence.** All raw data and materials generated in the course of the  
250 present work are available upon request.

251

252

253 **Figure & Figure Legends:**




254

255 **Figure 1: Sting Deficiency Leads to Global Metabolic Improvement.**

- 256 (A) *Cxcl10*, *Tnf-α* and *Il6* mRNA levels were measured in liver, muscle and visceral fat from  
257 *Sting*<sup>+/+</sup> (n=5) and *Sting*<sup>-/-</sup> (n=5) mice.
- 258 (B) Body weight of *Sting*<sup>+/+</sup> (n=32) and *Sting*<sup>-/-</sup> (n=34) mice under normal diet.
- 259 (C) Body composition of *Sting*<sup>+/+</sup> (n=6) and *Sting*<sup>-/-</sup> (n=6) mice was assessed by EchoMRI.
- 260 (D) Food intake of *Sting*<sup>+/+</sup> (n=8) and *Sting*<sup>-/-</sup> (n=9) mice.
- 261 (E) Insulin tolerance test (ITT) in *Sting*<sup>+/+</sup> (n=14) and *Sting*<sup>-/-</sup> (n=15) mice. Left panel: Glycemia  
262 (mg/dL) over time, following a bolus of Insulin. Right panel, area above the curve.

263 (F) Glucose tolerance test (GTT) was performed in  $\text{Sting}^{+/+}$  (n=25) and  $\text{Sting}^{-/-}$  (n=24) mice.  
264 Left panel: Glycemia (mg/dL) over time, following a bolus of Glucose. Right panel, area under  
265 the curve (AUC).  
266 (G) Pyruvate tolerance test (PTT) was performed in  $\text{Sting}^{+/+}$  (n=7) and  $\text{Sting}^{-/-}$  (n=7) mice. Left  
267 panel: Glycemia (mg/dL) over time, following a bolus of Pyruvate. Right panel: AUC.  
268 (H) Oxygen consumption of  $\text{Sting}^{+/+}$  (n=6) and  $\text{Sting}^{-/-}$  (n=6) mice as determined in metabolic  
269 chambers.  
270 (I) Energy expenditure during day (white) and night (grey) was determined as in (H). P-value  
271 was determined by One-way Anova.  
272 (J) Daily profile of voluntary running-wheel activity of  $\text{Sting}^{+/+}$  (n=11) and  $\text{Sting}^{-/-}$  (n=10) mice.  
273 (K) Rectal temperature of  $\text{Sting}^{+/+}$  (n=13) and  $\text{Sting}^{-/-}$  (n=14) mice.  
274 (L) *Pgc1α* and *Ucp1* mRNA levels in the white adipose tissue from  $\text{Sting}^{+/+}$  (n=4) and  $\text{Sting}^{-/-}$   
275 (n=5) mice.  
276 (M) Survival curve of  $\text{Sting}^{+/+}$  (n=6) and  $\text{Sting}^{-/-}$  (n=7) mice under high fat diet (HFD 60%)  
277 All graphs present means  $\pm$  Standard Error of the Mean (SEM). P-value was determined by  
278 Student's t-test, unless otherwise stated. ns: not significant, \*: P < 0.05, \*\*P: < 0.01, \*\*\*P: <  
279 0.001.  
280




281

282 **Figure 2: Sting Interacts with Fads2 and Modulates Polyunsaturated Fatty Acids Pools.**

283 (A) Left: Experimental scheme. Right: silver-staining of immunopurified Flag- and HA-tagged  
284 Sting (F/HA-Sting) separated on SDS-PAGE. Numbers on the left: molecular weight in kDa.  
285 (B) Schematic representation of the LA (Omega-6, Yellow) and ALA (Omega-3, Blue) fatty  
286 acids (FA) desaturation pathway, leading to the generation of polyunsaturated FA (PUFAs).  
287 ALA: α-linolenic acid, LA: linoleic acid, DGLA: Dihomo-γ-linolenic acid, AA: arachidonic  
288 acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid


289 (C) Inputs and eluates from Flag-immunoprecipitated F/HA-Sting were analyzed by Western  
290 Blot (WB) using indicated antibodies.  
291 (D) Inputs and eluates from Flag-immunoprecipitated Flag-Fads2 were analyzed by WB using  
292 indicated antibodies.  
293 (E) Ratio between total Omega-6 and Omega-3 PUFAs and derivatives measured in Sting<sup>+/+</sup>  
294 (n=5) and Sting<sup>-/-</sup> (n=5) mice liver using LC-MS.  
295 (F) Sum of indicated PUFA and respective derivatives in samples analysed as in (E).  
296 (G) Fads1 and 2 enzyme activity was estimated by calculating the substrate/product ratio of  
297 PUFAs measured in (E).  
298 All graphs present means ± SEM. P-value was determined by Student's t-test. ns: not  
299 significant, \*: P < 0.05.  
300



301

302 **Figure 3: Activation-dependent Sting Degradation Promotes Fads2 Activity.**

- 303 (A) *Ifnβ* and *Cxcl10* mRNA levels in 293T cells transfected or not with dsDNA for 24h (n=3)
- 304 (B) Whole cell extracts (WCE) of cells treated as in (A) were analyzed by WB using indicated
- 305 antibodies.
- 306 (C) Sum of indicated PUFA and derivatives in samples prepared as in (A).
- 307 (D) Ratio between total Omega-6 and Omega-3 PUFAs and derivatives in samples from (C).
- 308 (E) *Ifnβ* and *Cxcl10* mRNA levels in WT-MEF (n=3) and MEF<sup>Trex1-/-</sup> (n=3).
- 309 (F) WCE from WT-MEF or MEF<sup>Trex1-/-</sup> were analyzed by WB using indicated antibodies.
- 310 (G) Sum of indicated PUFAs and derivatives in WT-MEF or MEF<sup>Trex1-/-</sup> (n=5).
- 311 (H) Ratio between total Omega-6 and Omega-3 PUFAs and derivatives in samples from (G).
- 312 All graphs present means ± SEM. P-value was determined by Student's t-test. \*: P < 0.05, \*\*P:
- 313 < 0.01, \*\*\*P: < 0.001.



314

315 **Figure 4: cGAMP and PUFAs Orchestrate the Crosstalk between Fads2 and Sting.**

316 (A) Molecular docking of cGAMP, DMXAA, and 6 PUFAs to STING (top) or FADS2  
 317 (bottom). Color coding for ligand: LA in blue, ALA in green, AA in orange, DHA in turquoise,  
 318 DGLA in brown, and EPA in magenta.  
 319 (B) Binding of Flag-purified F-Fads2 or F/HA-Sting to cGAMP was analysed by WB using  
 320 anti-Sting or anti-Fads2 antibodies.

321 (C) WCE from WT, Sting<sup>-/-</sup>, or cGas<sup>-/-</sup> MEF stimulated or not with DMXAA for 2 h were  
322 analyzed by WB using indicated antibodies.  
323 (D) *Ifnβ* and *Cxcl10* mRNA levels in WT-MEF stimulated or not with DMXAA in combination  
324 or not with ALA or LA (n=3).  
325 (E) WCE from MEF expressing non-targeting (shScr) or Fads2-targetting (shFads2) shRNAs,  
326 transfected or not with dsDNA for 6 h, were analyzed by WB using indicated antibodies.  
327 (F) *Ifnβ* and *Cxcl10* mRNA levels in cells expressing Scramble (scr) or Fads2-targeting shRNAs  
328 after stimulation or not with dsDNA for 6 h (n=4).  
329 (G) WT-MEF were infected with HSV-KOS64 in presence or not of a Fads2 inhibitor  
330 (sc26196). Infection is presented as mean lysis area per cm<sup>2</sup>.  
331 (H) Schematic representation of the crosstalk between Sting and Fads2.  
332 All graphs are means ± SEM from at least 3 independent experiments. P-value was determined  
333 by Student's t-test.\*: P < 0.05, \*\*: P < 0.01, \*\*\*: P < 0.001  
334

335 **STAR Methods:**

336 *Animals.* Animal protocols were performed in accordance with French and European Animal  
337 Care Facility guidelines. All experiments were approved by the Animal Welfare and Ethical  
338 Review Body of Languedoc-Roussillon. Housing and experimental procedures were approved  
339 by the French Agriculture and Forestry Ministry (A34-172-13 & 15040-2018050214043878).  
340 Males from 8 to 14 weeks of age were used for this study. Mice Sting deficient  
341 (*Tmem173*<tm1Camb>) were provided by Pr. Lei Jin (Jin et al., 2013). cGAS deficient mice  
342 line was purchased from the EMMA consortium (Strasbourg, France). *Tmem173*<tm1Camb>  
343 mice (conditional ready) were crossed with mice expressing FLP recombinase to obtain Sting  
344 floxed mice. Specific *Tmem173* knock out was obtained by crossing homozygous  
345 *Tmem173*fl/fl mice with transgenic LysM-Cre mice (gift from Michael Hahne, IGMM,  
346 Montpellier) expressing the Cre recombinase under the control of a myeloid gene promoter.

347 *Mouse studies.* Body weight was measured at 8 weeks of age. Body composition (Fat and lean  
348 mass) was evaluated by quantitative nuclear magnetic resonance imaging (EchoMRI 3-in-1  
349 system; Echo Medical Systems, Houston, Texas) before metabolic chambers experiments.  
350 Metabolic rates in mice were measured by indirect calorimetry using a Comprehensive Lab  
351 Animal Monitoring System (CLAMS, Columbus Instruments) as previously described (Vila et  
352 al., 2019). Mice were housed individually in metabolic chambers with free access to water and  
353 food for 2 days for acclimatization before animals were returned to metabolic chambers and  
354 monitored for the next day for oxygen consumption (VO<sub>2</sub>), carbon dioxide production (VCO<sub>2</sub>),  
355 and food intake. Energy expenditure was calculated using the formula energy expenditure =  
356 (3.815 + 1.232 VO<sub>2</sub>/VCO<sub>2</sub>) × VO<sub>2</sub>, and normalized to lean body mass. Body temperature was  
357 assessed in mice using a RET-3 rectal probe (Kent Scientific). ITTs and GTTs were performed  
358 as previously described (Vila et al., 2014). Briefly, mice were fasted for 6 h with free access to  
359 drinking water. For ITTs, insulin was administered intraperitoneally (0.4 mU/g of mice fed  
360 normal chow), and blood glucose was measured at various times after injection from the tip of  
361 the tail with a Glucometer (Accu-Chek, Roche). For GTTs, d-glucose was administered  
362 intraperitoneally (2 g/kg of mice), and blood glucose levels were monitored. At 15 min after  
363 glucose injection, blood was collected for insulin quantitation. Serum insulin concentrations  
364 were determined by ELISA (Mouse Ultrasensitive Insulin ELISA, ALPCO Diagnostics). For  
365 PTT, mice were fasted for 18 h, followed by intraperitoneal injection of pyruvate (2 g/kg of  
366 mice), and blood glucose levels were monitored. To measure spontaneous locomotion and  
367 circadian behaviour, mice were housed individually in cages equipped with a running wheel.

368 Voluntary activity was measured as running wheel revolutions recorded in one-minute bins and  
369 analysed with the ClockLab software (Actimetrics). Circadian behaviour was accessed during  
370 a period of light/dark cycle and under constant darkness as previously described (Abitbol et al.,  
371 2017). HSV-1 brain infections in mice were conducted as previously described (Reinert et al.,  
372 2021).

373 *Diets.* At the age of 8 weeks mice were fed with HFD (60% energy as fat, Safe Diet).

374 *RNA Extraction and Real-Time PCR.* Total RNA from tissues was extracted with Trizol reagent  
375 (Invitrogen) and RNA extraction kit (Sigma). RNA was quantified with a Nanodrop  
376 spectrophotometer (ND-1000, Nanodrop Technologies). RNA (1-2 µg) was reverse transcribed  
377 using SuperScript IV reverse transcriptase (Invitrogen). Expression of specific mRNAs was  
378 determined with a LightCycler (Roche) using the SYBR green PCR master mix (Takara).  
379 Reactions were performed in duplicate, and relative amounts of cDNA were normalized to  
380 Glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and/or heat shock protein 90 (Hsp90).  
381 RT-qPCR primer sequences are:

382 Human:

383 hGapdh: F-CTGGCGTCTTCACCACCATGG; R-CATCACGCCACAGTTCCGG;

384 hIfnβ: F-GAATGGGAGGCTTGAATACTGCCT;

385 R-TAGCAAAGATGTTCTGGAGCATCTC;

386 Mouse:

387 mGapdh: F-TTCACCACCATGGAGAAGGC; R-GGCATCGACTGTGGTCATGA;

388 mIfnβ: F-CTGCGTCCCTGCTGTGCTTCTCCA; R-TTCTCCGTCATCTCCATAGGGATC;

389 mCxcl10: F-ATGACGGGCCAGTGAGAATG; R-TCAACACGTGGGCAGGATAG;

390 mHsp90: F-GTCCGCCGTGTGTTCATCAT; R-GCACTTCTGACGATGTTCTTGC;

391 mTnf-α: F-CTGTAGCCCACGTCGTAGC; R-TTGAGATCCATGCCGTTG;

392 mUcp-1: F-CCTGCCTCTCGGAAACAA; R-TGTAGGCTGCCAACATGAACA;

393 mIl-6: F-GACTTCCATCCAGTTGCCTTCT; R-TCCTCTCCGGACTTGTGAAGTA

394 mPgc1α: F-AAAGGATGCGCTCTCGTTCA; R-GGAATATGGTATCGGGAAACA

395 mPrdm16: F-CAGCACGGTGAAGCCATT; R-GCGTCGATCCGCTTGTG

396

397 *Western Blot Analysis.* Tissues were homogenized using a Fastprep apparatus (MP) in a buffer  
398 containing 50 mM Tris-HCl (pH 8.0), 150 mM NaCl, 1% NP40, 0.5% Sodium deoxycholate,  
399 0.1% SDS, 10 µl/ml protease inhibitor, 10 µl/ml phosphatase I inhibitor, and 10 µl/ml  
400 phosphatase II inhibitor. Cells were lysed in 5 packed cell volume of TENTG-150 [20 mM tris-

401 HCl (pH 7.4), 0.5 mM EDTA, 150 mM NaCl, 10 mM KCl, 0.5% Triton X-100, 1.5 mM MgCl<sub>2</sub>,  
402 and 10% glycerol, supplemented with 10 mM β-mercaptoethanol, 0.5 mM PMSF and 1x  
403 phosphatase inhibitor] for 30 min at 4°C. Tissue and cell lysates were centrifuged at 14,000 g  
404 for 30 min at 4°C, and supernatants were stored at -80°C. Solubilized proteins (20-30 µg) from  
405 tissues or cells were run on 10% or 12% SDS-PAGE gels (Invitrogen Novex Tris-glycine)  
406 transferred onto nitrocellulose membrane (Biorad Trans blot turbo) and incubated with primary  
407 antibodies. Primary antibodies used include: anti-phospho IRF3 (1:500; Cell Signaling 4D4G),  
408 anti-IRF3(1:1000; Cell Signaling D6I4C), anti-phospho TBK1 (1:1000; Cell Signaling  
409 D52C2), anti-TBK1 (1:1000; Cell Signaling D1B4), anti-STING (1:1000; Cell Signaling  
410 D2P2F), anti-phospho STING (1:1000; Cell Signaling D8F4W), anti-glyceraldehyde-  
411 phosphate dehydrogenase (GAPDH; 1:5000; Proteintech Europe 800004-1-Ig), anti-TREX-1  
412 (1:250; Santa Cruz Biotechnology C-11 sc133112), mouse specific anti-cGAS (1:1000; Cell  
413 Signaling D3080), anti-HSP90 (1:1000; Cell Signaling C45G5), and anti-FADS2 (1:10 000;  
414 Invitrogen PA5-87765). All secondary antibodies (Cell Signaling) were used at 1:2000 dilution.  
415 Immunoreactive proteins were visualized by chemiluminescence (SuperSignal West Pico or  
416 femto Thermo Scientific).

417 *Cells and cell cultures.* 293T, T98G, WT-MEF, MEF-Sting<sup>-/-</sup>, MEF-cGas<sup>-/-</sup> were maintained in  
418 DMEM supplemented with 10% Fetal Bovine Serum (FBS), 1% Penicillin/Streptomycin and  
419 1% Glutamine. MEF-Sting<sup>-/-</sup> overexpressing FLAG- and HA-tagged Sting (F/HA-Sting) were  
420 generated by transducing MEF-Sting<sup>-/-</sup> with retroviral particles packaging the pOZ-F/HA-Sting  
421 construct and selection with puromycin. WT-MEF overexpressing FLAG-tagged Fads2 (Flag-  
422 Fads2) were generated by transducing WT-MEF with retroviral particles packaging the pOZ-  
423 Flag-Fads2 construct and selection with puromycin. The T98G IRF3 and control knockout cell  
424 line was generated using LenticrisprV2-GFP system (Plasmid #82416) and cell sorting using a  
425 BD FACS Melody. Pooled cells were then amplified and IRF3 invalidation verified by Western  
426 Blot analysis.

427 *Cell treatment and transfection.* Cells were transfected with JetPrime transfection reagent  
428 (Polyplus) at 1:2 ratio with various nucleic acids at 2 µg/ml. DMXAA (Invivogen) was used at  
429 100 or 200 µM in Opti-MEM (Gibco). Sc26196 (Santa Cruz) was used at 2 µM.

430 *HSV-KOS64 amplification.* HSV KOS-64-GFP strain was a gift from S. Paludan. The virus was  
431 amplified in Vero cells. Briefly, Vero cells were plated in T175 and infected with HSV KOS-  
432 64-GFP virus during 30 min. Media was subsequently replaced and cells were collected 72 h  
433 after infection for viral extraction using 3 freeze-thaw cycles. Two centrifugations steps were

434 performed and concentrated virus was resuspended before storage at -80°C. 10<sup>3</sup> cells were  
435 seeded in 96-wells plate for lysis area number or 2.10<sup>5</sup> 6-wells plate for western blot 16h prior  
436 infection. Cells were infected with HSV KOS-64-GFP for 90min on presence or not of Fads2  
437 inhibitor (2μM). Medium was replaced with DMEM/Human serum 2% medium for 16h. For  
438 lysis area number assessment, medium was replaced with DMEM/FBS 10% medium for 32h.

439 *Immunoprecipitation and mass spectrometry analysis.* MEF-Sting<sup>-/-</sup> overexpressing F/HA-  
440 Sting were lysed in 5 packed cell volume of TENTG-150. The first immunoprecipitation used  
441 an anti-FLAG antibody, followed by the elution using an excess of FLAG peptide. Eluates were  
442 subsequently used as input material for immunoprecipitation using an anti-HA antibody. Sting  
443 protein partners were eluted using an excess of HA peptide. Part of the FLAG and HA  
444 immunoprecipitated material was silver-stained and the remainder Coomassie-stained. Portions  
445 of the Coomassie-stained gel were excised and analyzed by Mass Spectrometry.

446 *In vitro pull-down using biotinylated cGAMP.* Pull-down was carried out using 30 μl (0.3mg)  
447 of MyOne Streptavidin C1 Dynabeads per condition. An excess of Biotin or cGAMP was  
448 coupled to beads according to the manufacturer's instructions. 30 μl of Flag-  
449 immunoprecipitated Fads2 or Sting was incubated with beads, on ice for 30 min in low-binding  
450 tubes (Axygen). Three consecutive washes were performed in 20 mM tris-HCl (pH 7.4), 10mM  
451 KCl, 0.5% Triton, 150 mM NaCl, 10% glycerol, 1.5 mM MgCl<sub>2</sub> and 10 mM β-  
452 mercaptoethanol, and 0.5 mM PMSF. Tubes were changed at first and last washes. Bound  
453 material was eluted in 30 μl of Laemmli buffer.

454 *RNA interference.* shRNA targeting Fads2 (Clone ID: NM\_019699.1-487s1c1) and scramble  
455 (SHC016) were obtained from Sigma-Aldrich. shRNA-expressing lentiviral particles were  
456 produced by co-transfection of 2 × 10<sup>6</sup> 293T cells with 5 μg of shFads2, 5 μg of psPAX2 (Gag-  
457 Pol), and 1 μg of pMD2G (Env), using the standard calcium-phosphate transfection protocol.  
458 Viral particles were harvested 48 h after transfection, filtered with 0.45 μM filters, and used for  
459 transduction. For knockdown of Fads2, 10<sup>6</sup> MEF cells were seeded 24 h before transduction.  
460 Medium was replaced 10 h after transduction, and 1.5μg/ml puromycin selection was  
461 performed 72 h later.

462 *Measurement of PUFAs and oxilipins in biological samples.* Snap-frozen tissues samples or 3×  
463 10<sup>6</sup> cells were crushed and solubilized (sonicated) in 1 mL of methanol (Wako, Tokyo, Japan).  
464 The samples were then spiked with following 16 internal standards (at 30 μM final  
465 concentration): tetranor-PGEM-d6, 6-keto-PGF1a-d4, TXB2-d4, PGF2a-d4, PGE2-d4, PGD2-

466 d4, LTC4-d5, LTB4-d4, 15-HETE-d8, 12-HETE-d8, 5-HETE-d8, PAF-d4, OEA-d4, EPA-d5,  
467 DHA-d5, DHA-d5 and AA-d8 (all from Cayman Chemicals, Ann Arbor, MI, USA). The  
468 samples were then sonicated for 10 s, then vortexed for 2 min and further incubated for 2h at  
469 4°C. Next, the samples were centrifuged at 15.000g for 10 min, the supernatant was removed  
470 and diluted with 4 mL of 0.1 % formic acid. The mix was briefly vortexed and loaded on the  
471 solid phase extraction (SPE) column Strata-X (Phenomenex, Torrance, CA, USA) in 1 ml steps.  
472 Before loading the sample, the SPE column was washed with 1 mL methanol and equilibrated  
473 with 2 mL of 0.1% formic acid. Following sample loading, the SPE column was washed with  
474 1 mL 0.1% formic acid, 1 mL 15% ethanol and the compounds were eluted in 250 µL methanol.  
475 The eluate was lyophilized and then solubilized in 20 µL methanol, of which 5 µL sample were  
476 injected on UPLC coupled to triple-quadrupole MS (LCMS-8050). The sample was separated  
477 using analytical column Kinetex C8 (Cat. # 00F-4497-AN; Phenomenex), mobile phase A 0.1%  
478 formic acid (Sigma Aldrich) in water and mobile phase B acetonitrile (Sigma Aldrich). The  
479 flow rate was set at 0.4 mL/min, column oven temperature at 40°C. The gradient was: 0 min  
480 90% A, 5 min 75% A, 10 min 65% A, 20 min 25% A, 20.1 – 25 min 5% A, 25.1 min 90% A.  
481 MS setting, data acquisition and data analysis were performed according to manufacturer  
482 instructions for analyzing Lipid Mediators version 2.0 (Cat. # 225-24873A, Shimadzu).

483 *LC-MS data analysis.* Following visual inspection, integration and calculation of peak surface  
484 area for all identified compounds, the data were normalized using the internal standards. As  
485 outlined in the Lipid Mediators version 2.0 manual, individual compounds were repartitioned  
486 in 17 different groups, which were then normalized with 17 internal standards outlined above.  
487 Next, for each sample we calculated total metabolite load (TML), which was equal to the sum  
488 of individual metabolites measured in the respective sample. For TML calculation, missing  
489 values for individual metabolites were imputed by assigning the least possible peak area found  
490 in the dataset. The imputation was based on the hypothesis that as long as a given metabolite  
491 was present in some of the samples, its absence in other samples was due to the limit of detection  
492 of the analysis. All values for all metabolites within a sample were normalized with respect to  
493 TML. Once the normalized quantities were calculated, the data were imported in R (4.0.2) [R  
494 Core Team (2020)] and analyzed using the MetaboAnalyst package (4.0) (Chong et al., 2019).

495 *Homology Modelling.* The homology modelling of the FADS2 was performed using the  
496 Molecular Operating Environment (MOE) Suite (Warde-Farley et al., 2010). The 3OZZ RCSB  
497 entry was used as template, which is the crystal structure of the *Bos taurus* cytochrome b5 core-  
498 swap mutant. The 3D models were subsequently energetically optimized the AMBER10

499 forcefield as it is implemented in the MOE Suite. Finally, all 3D models were assessed for their  
500 folding via the protein and geometry check of MOE Suite.

501 *Molecular Docking.* The docking module of MOE was used for the docking of the 6 PUFAs or  
502 cGAMP/DMXAA to STING and the FADS2 model. The 6 PUFAs that were used were namely:  
503 linoleic acid (LA),  $\alpha$ -linolenic acid (ALA), dihomo- $\gamma$ -linolenic acid (DGLA), arachidonic acid  
504 (AA), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). A fast Fourier  
505 transformation (FFT) pipeline is utilized by MOE for the docking experiment. The overall score  
506 is influenced by the model's packing, electrostatic, solvation and hydrophobic energies.  
507 Transient complexes of proteins are kept in a local database and their contact propensities are  
508 statistically used for docking. The top hits of the docking experiment were energetically  
509 optimized using energy minimization pipelines to relieve the models from any residual  
510 geometrical strain. Finally, the Drugster suite was used to perform a final and rapid energy  
511 minimization step using AMBER99 forcefield (Vilar et al., 2008), while solvated using an  
512 implicit Generalized Born (GB) water model.

513 *Molecular Dynamics.* The interaction pattern and overall fold of the final complexes of each  
514 one of the 6 PUFAs or cGAMP/DMXAA to either STING and FADS2 model, were subjected  
515 to exhaustive molecular dynamics simulations using the DrugOn suite <sup>9</sup>. Molecular dynamics  
516 simulations were executed in an explicitly SPC water solvated periodic cube system. Counter-  
517 ions were used as required to neutralize the molecular system. Each biological system was  
518 subjected to a hundred nanoseconds (100 ns) of molecular dynamics at 300K and at 1 fs step  
519 size. The molecular trajectory of each simulation was then imported into a local database for  
520 further analysis (Vlachakis et al., 2013).

521

522 **Supplementary Information**

523 **Supplementary figure legends:**

524 **Figure S1: Sting Deficiency Leads to Global Metabolic Improvement**

525 (A) Insulinemia was measured 15 min after the injection of glucose during a glucose tolerance  
526 test (GTT) in *Sting*<sup>+/+</sup> (n=6) and *Sting*<sup>-/-</sup> (n=7) mice,

527 (B) Representative actograms of wheel activity measured under a 12 h light / 12 h dark schedule  
528 (yellow), and under constant darkness (blue) in *Sting*<sup>+/+</sup> (n=11) and *Sting*<sup>-/-</sup> (n=10) mice,

529 (C) *Ucp1* mRNA levels were measured in the brown adipose tissue from *Sting*<sup>+/+</sup> (n=5) and  
530 *Sting*<sup>-/-</sup> (n=6) mice,

531 (D) Body weight of cGas<sup>+/+</sup> (n=6) and cGas<sup>-/-</sup> (n=7) mice fed normal chow diet at 8 weeks age.

532 (E) GTT was performed in cGas<sup>+/+</sup> (n=5) and cGas<sup>-/-</sup> (n=5) mice,

533 (F) Rectal temperature was measured in cGas<sup>+/+</sup> (n=6) and cGas<sup>-/-</sup> (n=7) mice,

534 (G) Body weight of *Sting*-Flo<sup>+/+</sup> (n=7) and *Sting*-Flo<sup>LysM</sup> (n=8) mice fed normal chow diet at  
535 8 weeks of age,

536 (H) GTT was performed in *Sting*-Flo<sup>+/+</sup> (n=7) and *Sting*-Flo<sup>LysM</sup> (n = 6) mice,

537 (I) Rectal temperature of *Sting*-Flo<sup>+/+</sup> (n=9) and *Sting*-Flo<sup>LysM</sup> (n=8) mice.

538 All graph present means  $\pm$  SEM. P-values were determined by Student's t-test. ns: not  
539 significant.

540

541 **Figure S2: Sting Interacts with Fads2 and Modulates Polyunsaturated Fatty Acids Pools**

542 (A) Partial least squares discriminant analysis (PLS-DA) of liver samples from *Sting*<sup>+/+</sup> (pink)  
543 and *Sting*<sup>-/-</sup> (green) mice in which PUFAs and derivatives were measured by LC-MS (n=5 mice  
544 per group),

545 (B) Partial least squares discriminant analysis (PLS-DA) of white visceral adipose tissue  
546 samples from *Sting*<sup>+/+</sup> (pink) and *Sting*<sup>-/-</sup> (green) mice in which PUFAs and derivatives were  
547 measured by LC-MS (n=3 mice per group),

548 (C) Correlation plots of PUFAs and derivatives measured in samples from (A),

549 (D) Correlation plots of PUFAs and derivatives measured in samples from (B),

550 (E) Ratio between total Omega-6 and Omega-3 PUFAs and derivatives in WT, *Sting*<sup>-/-</sup>, or  
551 cGas<sup>-/-</sup> MEF samples,

552 (F) PUFAs and derivatives were measured in WT, *Sting*<sup>-/-</sup>, or cGas<sup>-/-</sup> MEF using LC-MS.

553 Graph presents the sum of indicated PUFA and respective derivatives.

554 In panels (C) and (D) the side bars indicate in green: derivatives of ALA (Omega-3), in red:  
555 derivatives from LA (Omega-6), in black: PUFAs that do not vary across the samples, in

556 yellow: PUFAs and derivatives increased by at least 30%, and in blue: PUFAs decreased by at  
557 least 30%.

558 All graph present means  $\pm$  SEM. P-values were determined by Student's t-test. ns: not  
559 significant. \*:  $P < 0.05$ , \*\*P:  $< 0.01$ , \*\*\*P:  $< 0.001$ .

560

561 **Figure S3: Activation-dependent Sting Degradation Promotes Fads2 Activity**

562 (A) *Pgc1α* and *Prdm16* mRNA levels in WT-MEFs cells after stimulation or not with dsDNA  
563 (2 $\mu$ g) for 6 h (n=4),

564 (B) Whole cell extracts (WCE) from control (CTL) or IRF3 knockout T98G cell lines  
565 stimulated or not for 6 h with dsDNA were analyzed by WB using indicated antibodies,

566 (C) *Ifnβ* mRNA levels from samples treated as in (B) were analyzed by RT-qPCR. Graph  
567 presents mean fold induction  $\pm$  SEM, as compared to unstimulated control cells (n=3),

568 (D) WCE from WT-MEFs, infected or not for 16 h with HSV-KOS64, were analyzed by WB  
569 using indicated antibodies. Multiplicity of infection (MOI) scale was from 1.5x10-4 to 1.5,

570 (E) Left: Representative mice brain samples infected or not for 5 days with the McKrae HSV-  
571 1 strain analyzed by WB using indicated antibodies. Right: Quantification of Fads2 protein  
572 levels in mice brain extracts following 5 days of infection or not with McKrae HSV1 (n=4),

573 (F) *Ifnβ* mRNA levels were quantified from mice brain samples treated as in (C)

574 All graph present means  $\pm$  SEM. P-values were determined by Student's t-test. ns: not  
575 significant. \*:  $P < 0.05$ , \*\*P:  $< 0.01$ , \*\*\*P:  $< 0.001$ .

576

577 **Figure S4: cGAMP and PUFAs Orchestrate the Crosstalk between Fads2 and Sting**

578 (A) PUFAs interact with the cGAMP-binding domain of Sting. 2D molecular interaction maps  
579 for cGAMP, DMXAA and the 6 PUFAs docked into STING (left column) and FADS2 (right  
580 column). LA: linoleic acid, DGLA: Dihomo- $\gamma$ -linolenic acid, AA: arachidonic acid, ALA: $\alpha$ -  
581 linolenic acid, EPA: eicosapentaenoic acid, DHA: docosahexaenoic acid,

582 (B) WCE from WT, Sting-/-, or cGas-/- MEF stimulated or not dsDNA (2 $\mu$ g) for 6h (left) or  
583 24 h (right) were analyzed by WB using indicated antibodies,

584 (C) PUFAs measured in cells expressing Scramble (scr) or Fads2-targeting shRNAs using LC-  
585 MS. Graph presents indicated PUFA,

586 (D) *Prdm16* mRNA levels in cells expressing Scramble (scr) or Fads2-targeting shRNAs after  
587 stimulation or not with dsDNA for 6 h (n=4).

588 All graph present means  $\pm$  SEM. P-values were determined by Student's t-test. ns: not  
589 significant. \*:  $P < 0.05$ , \*\*P:  $< 0.01$ .

590

591 **Supplementary Tables:**

592 **Table S1.** Major protein partners of Sting identified by Mass Spectrometry. \* Unique peptides  
593 identified in Mock IP. \*\*: Unique peptides identified in F/HA-Sting IP. MW is in kDa. IP:  
594 immunoprecipitation.

Uniprot Reference	Gene Symbol	MW	Mock	IP
sp Q9WUN2 TBK1_MOUSE	Tbk1	83.37	0	8
sp Q9Z0R9 FADS2_MOUSE	Fads2	52.35	0	10
sp Q920L1 FADS1_MOUSE	Fads1	52.29	0	6
sp Q9D6K9 CERS5_MOUSE	Cers5	48.13	0	5
sp Q9CY27 TECR_MOUSE	Tecr	36.07	0	5
sp Q8VCH6 DHC24_MOUSE	Dhcr24	60.07	0	4
sp Q6NVG1 LPCT4_MOUSE	Lpcat4	57.11	0	4
sp Q8K2C9 HACD3_MOUSE	Hacd3	43.10	0	2
sp P47740 AL3A2_MOUSE	Aldh3a2	53.94	0	2

595

596 **Table S2.** Interaction energies of the docked cGAMP, DMXAA and the 6 PUFAs on Sting and  
597 Fads2 proteins. Energies are in Kcal/mol.

	STING	FADS2
cGAMP	-34.925	-7.269
DMXAA	-24.400	-51.661
linoleic acid (LA)	-39.483	-57.098
dihomo-γ-linolenic acid (DGLA)	-13.064	-47.331
arachidonic acid (AA)	-42.827	-58.912
α-linolenic acid (ALA)	-43.658	-38.473
eicosapentaenoic acid (EPA)	-24.926	-41.078
docosahexaenoic acid (DHA)	-53.608	-57.339

598

599 **References:**

600 Abitbol, K., Debiesse, S., Molino, F., Mesirca, P., Bidaud, I., Minami, Y., Mangoni, M.E., Yagita, K.,  
601 Mollard, P., and Bonnefont, X. (2017). Clock-dependent and system-driven oscillators interact in the  
602 suprachiasmatic nuclei to pace mammalian circadian rhythms. PLoS One 12, e0187001.

- 603 Ablasser, A., Goldeck, M., Cavlar, T., Deimling, T., Witte, G., Röhl, I., Hopfner, K.P., Ludwig, J., and  
604 Hornung, V. (2013). cGAS produces a 2'-5'-linked cyclic dinucleotide second messenger that activates  
605 STING. *Nature* **498**, 380-384.
- 606 Ablasser, A., Hemmerling, I., Schmid-Burgk, J.L., Behrendt, R., Roers, A., and Hornung, V. (2014). TREX1  
607 deficiency triggers cell-autonomous immunity in a cGAS-dependent manner. *Journal of immunology*  
608 (Baltimore, Md. : 1950) **192**, 5993-5997.
- 609 Baazim, H., Schweiger, M., Moschinger, M., Xu, H., Scherer, T., Popa, A., Gallage, S., Ali, A., Khamina,  
610 K., Kosack, L., et al. (2019). CD8(+) T cells induce cachexia during chronic viral infection. *Nature*  
611 *immunology* **20**, 701-710.
- 612 Bai, J., Cervantes, C., Liu, J., He, S., Zhou, H., Zhang, B., Cai, H., Yin, D., Hu, D., Li, Z., et al. (2017). DsbA-  
613 L prevents obesity-induced inflammation and insulin resistance by suppressing the mtDNA release-  
614 activated cGAS-cGAMP-STING pathway. *Proceedings of the National Academy of Sciences of the*  
615 *United States of America* **114**, 12196-12201.
- 616 Belchior, T., Paschoal, V.A., Magdalon, J., Chimin, P., Farias, T.M., Chaves-Filho, A.B., Gorjao, R., St-  
617 Pierre, P., Miyamoto, S., Kang, J.X., et al. (2015). Omega-3 fatty acids protect from diet-induced obesity,  
618 glucose intolerance, and adipose tissue inflammation through PPARgamma-dependent and  
619 PPARgamma-independent actions. *Mol Nutr Food Res* **59**, 957-967.
- 620 Berra, A., Tau, J., Zapata, G., and Chiaradia, P. (2017). Effects of PUFAs in a Mouse Model of HSV-1  
621 Chorioretinitis. *Ocul Immunol Inflamm* **25**, 844-854.
- 622 Brestoff, J.R., and Artis, D. (2015). Immune regulation of metabolic homeostasis in health and disease.  
623 *Cell* **161**, 146-160.
- 624 Buck, M.D., Sowell, R.T., Kaech, S.M., and Pearce, E.L. (2017). Metabolic Instruction of Immunity. *Cell*  
625 **169**, 570-586.
- 626 Chong, J., Wishart, D.S., and Xia, J. (2019). Using MetaboAnalyst 4.0 for Comprehensive and Integrative  
627 Metabolomics Data Analysis. *Curr Protoc Bioinformatics* **68**, e86.
- 628 Derosa, G., Cicero, A.F., D'Angelo, A., Borghi, C., and Maffioli, P. (2016). Effects of n-3 pufas on fasting  
629 plasma glucose and insulin resistance in patients with impaired fasting glucose or impaired glucose  
630 tolerance. *Biofactors* **42**, 316-322.
- 631 DiNicolantonio, J.J., and O'Keefe, J.H. (2018). Importance of maintaining a low omega-6/omega-3 ratio  
632 for reducing inflammation. *Open Heart* **5**, e000946.
- 633 Fan, R., Koehler, K., and Chung, S. (2019). Adaptive thermogenesis by dietary n-3 polyunsaturated fatty  
634 acids: Emerging evidence and mechanisms. *Biochim Biophys Acta Mol Cell Biol Lipids* **1864**, 59-70.
- 635 Fernández-Galilea, M., Félix-Soriano, E., Colón-Mesa, I., Escoté, X., and Moreno-Aliaga, M.J. (2020).  
636 Omega-3 fatty acids as regulators of brown/beige adipose tissue: from mechanisms to therapeutic  
637 potential. *Journal of physiology and biochemistry* **76**, 251-267.
- 638 Gabbs, M., Leng, S., Devassy, J.G., Moniruzzaman, M., and Aukema, H.M. (2015). Advances in Our  
639 Understanding of Oxylipins Derived from Dietary PUFAs. *Advances in nutrition* (Bethesda, Md.) **6**, 513-  
640 540.
- 641 Galland, L. (2010). Diet and inflammation. *Nutrition in clinical practice : official publication of the*  
642 *American Society for Parenteral and Enteral Nutrition* **25**, 634-640.
- 643 Gao, D., Wu, J., Wu, Y.T., Du, F., Aroh, C., Yan, N., Sun, L., and Chen, Z.J. (2013a). Cyclic GMP-AMP  
644 synthase is an innate immune sensor of HIV and other retroviruses. *Science* (New York, N.Y.) **341**, 903-  
645 906.
- 646 Gao, P., Ascano, M., Wu, Y., Barchet, W., Gaffney, B.L., Zillinger, T., Serganov, A.A., Liu, Y., Jones, R.A.,  
647 Hartmann, G., et al. (2013b). Cyclic [G(2',5')pA(3',5')p] is the metazoan second messenger produced by  
648 DNA-activated cyclic GMP-AMP synthase. *Cell* **153**, 1094-1107.
- 649 Ghandour, R.A., Colson, C., Giroud, M., Maurer, S., Rekima, S., Ailhaud, G., Klingenspor, M., Amri, E.Z.,  
650 and Pisani, D.F. (2018). Impact of dietary omega3 polyunsaturated fatty acid supplementation on  
651 brown and brite adipocyte function. *J Lipid Res* **59**, 452-461.
- 652 Gonzalez-Periz, A., Horrillo, R., Ferre, N., Gronert, K., Dong, B., Moran-Salvador, E., Titos, E., Martinez-  
653 Clemente, M., Lopez-Parra, M., Arroyo, V., et al. (2009). Obesity-induced insulin resistance and hepatic

- 654 steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. *FASEB J* 23, 1946-  
655 1957.
- 656 Haag, S.M., Gulen, M.F., Reymond, L., Gibelin, A., Abrami, L., Decout, A., Heymann, M., van der Goot,  
657 F.G., Turcatti, G., Behrendt, R., et al. (2018). Targeting STING with covalent small-molecule inhibitors.  
658 *Nature* 559, 269-273.
- 659 Ishikawa, H., Ma, Z., and Barber, G.N. (2009). STING regulates intracellular DNA-mediated, type I  
660 interferon-dependent innate immunity. *Nature* 461, 788-792.
- 661 Jin, L., Getahun, A., Knowles, H.M., Mogan, J., Akerlund, L.J., Packard, T.A., Perraud, A.L., and Cambier,  
662 J.C. (2013). STING/MPYS mediates host defense against *Listeria monocytogenes* infection by regulating  
663 Ly6C(hi) monocyte migration. *Journal of immunology (Baltimore, Md. : 1950)* 190, 2835-2843.
- 664 King, K.R., Aguirre, A.D., Ye, Y.X., Sun, Y., Roh, J.D., Ng, R.P., Jr., Kohler, R.H., Arlauckas, S.P., Iwamoto,  
665 Y., Savol, A., et al. (2017). IRF3 and type I interferons fuel a fatal response to myocardial infarction.  
666 *Nature medicine* 23, 1481-1487.
- 667 Konno, H., Konno, K., and Barber, G.N. (2013). Cyclic dinucleotides trigger ULK1 (ATG1)  
668 phosphorylation of STING to prevent sustained innate immune signaling. *Cell* 155, 688-698.
- 669 Leonard, A.E., Kelder, B., Bobik, E.G., Chuang, L.T., Parker-Barnes, J.M., Thurmond, J.M., Kroeger, P.E.,  
670 Kopchick, J.J., Huang, Y.S., and Mukerji, P. (2000). cDNA cloning and characterization of human Delta5-  
671 desaturase involved in the biosynthesis of arachidonic acid. *The Biochemical journal* 347 Pt 3, 719-724.
- 672 Lira, F.S., Rosa Neto, J.C., Antunes, B.M., and Fernandes, R.A. (2014). The relationship between  
673 inflammation, dyslipidemia and physical exercise: from the epidemiological to molecular approach.  
674 *Curr Diabetes Rev* 10, 391-396.
- 675 Liu, S., Cai, X., Wu, J., Cong, Q., Chen, X., Li, T., Du, F., Ren, J., Wu, Y.T., Grishin, N.V., et al. (2015).  
676 Phosphorylation of innate immune adaptor proteins MAVS, STING, and TRIF induces IRF3 activation.  
677 *Science (New York, N.Y.)* 347, aaa2630.
- 678 Nakamura, M.T., and Nara, T.Y. (2004). Structure, function, and dietary regulation of delta6, delta5,  
679 and delta9 desaturases. *Annual review of nutrition* 24, 345-376.
- 680 Ralston, J.C., Matravadia, S., Gaudio, N., Holloway, G.P., and Mutch, D.M. (2015). Polyunsaturated fatty  
681 acid regulation of adipocyte FADS1 and FADS2 expression and function. *Obesity (Silver Spring, Md.)* 23,  
682 725-728.
- 683 Reinert, L.S., Rashidi, A.S., Tran, D.N., Katzilieris-Petras, G., Hvidt, A.K., Gohr, M., Fruhwurth, S., Bodda,  
684 C., Thomsen, M.K., Vendelbo, M.H., et al. (2021). Brain immune cells undergo cGAS/STING-dependent  
685 apoptosis during herpes simplex virus type 1 infection to limit type I IFN production. *J Clin Invest* 131.
- 686 Seale, P., Kajimura, S., Yang, W., Chin, S., Rohas, L.M., Uldry, M., Tavernier, G., Langin, D., and  
687 Spiegelman, B.M. (2007). Transcriptional control of brown fat determination by PRDM16. *Cell Metab*  
688 6, 38-54.
- 689 Sen, T., Rodriguez, B.L., Chen, L., Corte, C.M.D., Morikawa, N., Fujimoto, J., Cristea, S., Nguyen, T., Diao,  
690 L., Li, L., et al. (2019). Targeting DNA Damage Response Promotes Antitumor Immunity through STING-  
691 Mediated T-cell Activation in Small Cell Lung Cancer. *Cancer Discov* 9, 646-661.
- 692 Sirtori, C.R., and Galli, C. (2002). N-3 fatty acids and diabetes. *Biomed Pharmacother* 56, 397-406.
- 693 Sun, L., Wu, J., Du, F., Chen, X., and Chen, Z.J. (2013). Cyclic GMP-AMP synthase is a cytosolic DNA  
694 sensor that activates the type I interferon pathway. *Science (New York, N.Y.)* 339, 786-791.
- 695 Tosi, F., Sartori, F., Guarini, P., Olivieri, O., and Martinelli, N. (2014). Delta-5 and delta-6 desaturases:  
696 crucial enzymes in polyunsaturated fatty acid-related pathways with pleiotropic influences in health  
697 and disease. *Advances in experimental medicine and biology* 824, 61-81.
- 698 Vila, I.K., Badin, P.M., Marques, M.A., Monbrun, L., Lefort, C., Mir, L., Louche, K., Bourlier, V., Roussel,  
699 B., Gui, P., et al. (2014). Immune cell Toll-like receptor 4 mediates the development of obesity- and  
700 endotoxemia-associated adipose tissue fibrosis. *Cell Rep* 7, 1116-1129.
- 701 Vila, I.K., Park, M.K., Setijono, S.R., Yao, Y., Kim, H., Badin, P.M., Choi, S., Narkar, V., Choi, S.W., Chung,  
702 J., et al. (2019). A muscle-specific UBE2O/AMPKalpha2 axis promotes insulin resistance and metabolic  
703 syndrome in obesity. *JCI Insight* 4.

- 704 Vilar, S., Cozza, G., and Moro, S. (2008). Medicinal chemistry and the molecular operating environment  
705 (MOE): application of QSAR and molecular docking to drug discovery. *Curr Top Med Chem* 8, 1555-  
706 1572.
- 707 Vlachakis, D., Tsagrasoulis, D., Megalooikonomou, V., and Kossida, S. (2013). Introducing Drugster: a  
708 comprehensive and fully integrated drug design, lead and structure optimization toolkit.  
709 *Bioinformatics* 29, 126-128.
- 710 Warde-Farley, D., Donaldson, S.L., Comes, O., Zuberi, K., Badrawi, R., Chao, P., Franz, M., Grouios, C.,  
711 Kazi, F., Lopes, C.T., et al. (2010). The GeneMANIA prediction server: biological network integration for  
712 gene prioritization and predicting gene function. *Nucleic Acids Res* 38, W214-220.
- 713 Wu, J.J., Zhao, L., Hu, H.G., Li, W.H., and Li, Y.M. (2020). Agonists and inhibitors of the STING pathway:  
714 Potential agents for immunotherapy. *Medicinal research reviews* 40, 1117-1141.
- 715 Zhang, C., Hu, Z., Wang, K., Yang, L., Li, Y., Schluter, H., Yang, P., Hong, J., and Yu, H. (2020). Lipidomic  
716 profiling of virus infection identifies mediators that resolve herpes simplex virus-induced corneal  
717 inflammatory lesions. *Analyst* 145, 3967-3976.
- 718 Zhang, X., Shi, H., Wu, J., Zhang, X., Sun, L., Chen, C., and Chen, Z.J. (2013). Cyclic GMP-AMP containing  
719 mixed phosphodiester linkages is an endogenous high-affinity ligand for STING. *Molecular cell* 51, 226-  
720 235.

721